이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

근심 뇌종염/만성 피로 증후군 (ME/CFS)에서 리툭시 맙의 효능 및 안전성에 대한 연구

2026년 11월 10일 업데이트: National Center of Neurology and Psychiatry, Japan

근육질 뇌종염/만성 피로 증후군 (ME/CFS)에서 리툭시 맙 (유전 적 재조합)의 효능 및 안전성에 대한 탐색 적, 위약 대조, 이중 맹검, 이중 맹검, 2 상 연구.

The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.

연구 개요

상세 설명

The efficacy and safety of rituximab (genetical recombination), a CD20 antibody, on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Tokyo
      • Kodaira, Tokyo, 일본, 187-8551
        • 모병
        • National Center of Neurology and Psychiatry
        • 연락하다:
        • 수석 연구원:
          • Tomoko Okamoto, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Patients diagnosed with ME/CFS who meet the Canadian criteria by a physician.
  2. Patients with a severity score of 4 or higher on the Performance Status (PS) based ME/CFS severity classification by the Ministry of Health, Labour and Welfare Research Group
  3. Patients who are between 18 and 65 years of age at the time of obtaining written consent
  4. Patients who can be hospitalized (hospitalized from the day before administration and discharged the day after administration) at the time of the first dose of each of the primary and secondary evaluation periods
  5. Patients whose written consent has been obtained

Exclusion Criteria:

  1. Patients with a history of severe hypersensitivity or anaphylactic reactions to components of rituximab or products derived from mouse protein

  2. Patients whose cardiopulmonary function is judged by the treating physician to be not maintained

  3. Patients complaining of fatigue that does not meet the diagnostic criteria for ME/CFS

  4. Patients found to have other medical conditions that may cause symptoms

  5. Patients who are pregnant, lactating, or have a positive pregnancy test (serum human chorionic gonadotropin test) at the time of enrollment

  6. Patients with coexisting or pre-existing malignant tumors (excluding basal cell carcinoma of the skin and cervical dysplasia)

  7. Patients with coexisting or pre-existing severe immune system diseases (excluding autoimmune diseases such as thyroiditis and type 1 diabetes)

  8. Patients with a history of systemic immunosuppressive therapy (e.g., immunoglobulin therapy, azathioprine, cyclosporine, mycophenolate mofetil, etc.) within 1 year, a history of receiving drugs such as monoclonal antibodies acting on the immune system (e.g., anti-CD20 antibody products including rituximab), or a history of comorbidities requiring treatment with immunosuppressive drugs Patients with comorbidities requiring treatment with immunosuppressive agents (excluding treatment with low-dose steroids of 5 mg /day or less)

  9. Patients who have started alternative medicine (reference: acupuncture, moxibustion, and Japanese warm therapy) within 12 weeks prior to the start of treatment with the investigational drug.

  10. Patients with severe endogenous (primary) depression

  11. Patients with a neutrophil count <1.5*103/microliter and platelet count <10.0*104/microliter on blood test

  12. Patients with impaired renal function (serum creatinine level > 1.5 times the upper limit of the reference value at the institution)

  13. Patients with impaired hepatic function (serum bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) levels exceeding 1.5 times the upper limit of the reference value of the institution)

  14. Patients infected with Human Immunodeficiency Virus (HIV)

  15. Patients who test positive for at least one of Hepatitis B surface (HBs) antigen, HBs antibody, Hepatitis B core (HBc) antibody, or Hepatitis C virus (HCV) antibody.

    However, patients who meet the following conditions (1) and (2) may be registered.

    (i) Patients who are positive for HBs or HBc antibodies and whose HBV-DNA quantification is confirmed to be negative (less than detection sensitivity) and for whom appropriate monitoring, etc. can be conducted in accordance with the Guidelines for Hepatitis B Treatment edited by the Japan Society of Hepatology.

    (ii) For patients with positive HCV antibody, when HCV-RNA quantification is negative (less than detection sensitivity)

  16. Patients who do not have the ability to comply with the study protocol

  17. Patients who have participated in other clinical trials or clinical studies (except for observational studies without intervention) within 16 weeks prior to obtaining consent

  18. Other patients who are judged by the investigator or subinvestigator (hereinafter referred to as investigator) to be inappropriate to participate in this clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약

Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.

활성 비교기: 리툭시 맙 (유전 적 재조합)

Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Improvement rate
기간: From Baseline to the end of treatment at 24 weeks

Percentage of cases in which the severity score of ME/CFS based on PS by the MHLW research group improved by 1 or more compared to that before the start of study drug administration (week 0)

From Baseline to the end of treatment at 24 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
MHLW-PS 기반 ME/CFS 심각도 점수가 각 평가 지점 (개선 속도)에서 1 개 이상으로 개선 된 환자의 백분율 (0 주).
기간: 기준선에서 4 주 간격으로 4 주 간격으로 48
기준선에서 4 주 간격으로 4 주 간격으로 48
조사 약물 치료가 시작되기 전 각 평가 지점에서 MHLW 연구 그룹에 의한 PS에 기초한 ME/CFS의 심각도 점수의 변화량 (0 주)
기간: 기준선에서 4 주 간격으로 4 주 간격으로 48
기준선에서 4 주 간격으로 4 주 간격으로 48
Proportion of awake time spent in supine position (%),Proportion of awake time spent in sitting position (%)
기간: At 4-week intervals from Baseline up to Week 48

Changes in proportions will be aggregated.

At 4-week intervals from Baseline up to Week 48
Duration of standing and activity (hours)
기간: At 4-week intervals from Baseline up to Week 48

Changes in time will be aggregated.

At 4-week intervals from Baseline up to Week 48
Fatigue during rest and lying position
기간: At 4-week intervals from Baseline up to Week 48

Patients will be asked to report the level of fatigue they feel even while lying down, and changes in their fatigue levels will be aggregated.

At 4-week intervals from Baseline up to Week 48
Records on exertion and Post-Exertional Malaise (PEM)
기간: At 4-week intervals from Baseline up to Week 48

Patients will be asked to describe the specific activities they perform and the exhaustion they experience afterward, and a summary table will be created.

At 4-week intervals from Baseline up to Week 48
Assessment of fatigue during physical activity
기간: At 4-week intervals from Baseline up to Week 48

Patients will be asked to report the level of fatigue they experience during physical activity in daily life, and changes in fatigue levels will be aggregated.

At 4-week intervals from Baseline up to Week 48
Evaluation based on Fatigue Score
기간: At 2-week intervals from Baseline up to Week 48

Patients will be asked to complete the Fatigue Score questionnaire, and changes in the score will be aggregated.

At 2-week intervals from Baseline up to Week 48
SF-36
기간: At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the SF-36 questionnaire will be assessed to evaluate patients' quality of life.

At 12-week intervals from Baseline up to Week 48
COMPASS31
기간: At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the COMPASS31 questionnaire will be assessed to evaluate patients' autonomic symptoms.

At 12-week intervals from Baseline up to Week 48
Pittsburgh Sleep Quality Index (PSQI)
기간: At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the PSQI questionnaire will be assessed to evaluate patients' sleep quality.

At 12-week intervals from Baseline up to Week 48
Pain intensity
기간: At 12-week intervals from Baseline up to Week 48

Pain intensity will be assessed using the Visual Analogue Scale (VAS)

At 12-week intervals from Baseline up to Week 48
Grip strength
기간: At 12-week intervals from Baseline up to Week 48

Patients' grip strength will be measured, and changes in the measurements will be aggregated.

At 12-week intervals from Baseline up to Week 48
Analysis of the gut microbiota
기간: At 24-week intervals from Baseline up to Week 48

samples collected from patients will be analyzed, and the composition of the gut microbiota will be aggregated.

At 24-week intervals from Baseline up to Week 48
Brain imaging evaluation (Magnetic Resonance Imaging (MRI) of the head, Single Photon Emission Computed Tomography (SPECT) of cerebral blood flow)
기간: At 24-week intervals from Baseline up to Week 48

Findings from imaging will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (qPCR)
기간: At 24-week intervals from Baseline up to Week 48

qPCR will be measured, and changes in their levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (anti-autonomic receptor antibody analysis)
기간: At 24-week intervals from Baseline up to Week 48

Quantify the level of anti-autonomic receptor antibodies will be measured, and changes in their levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (immune cell subfractionation analysis)
기간: At 24-week intervals from Baseline up to Week 48

The subsets of immune cells will be measured, and changes in the levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Metabolome analysis
기간: At Baseline

A detailed characterization of the patients' metabolome at baseline will be conducted.

At Baseline
Adverse events
기간: From Baseline up to Week 48

The number of adverse events will be aggregated.

From Baseline up to Week 48
Vital signs (body temperature)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Vital signs (blood pressure)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Vital signs (pulse rate)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Serum immunoglobulins (IgG)
기간: At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Serum immunoglobulins (IgM)
기간: At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Serum immunoglobulins (IgA)
기간: At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Rituximab concentration of the blood plasma
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48

Rituximab concentration of the blood plasma

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
Blood drug concentration Anti-Drug Antibody (ADA)
기간: Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.

Summary statistics of ADA will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
B cells (CD19/CD20 positive cells) and T cells (CD3/CD4/CD8 positive cells)
기간: Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.

Summary statistics of B cells and T cells will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Tomoko Okamoto, MD, National Center of Neurology and Psychiatry

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 9일

기본 완료 (추정된)

2028년 5월 31일

연구 완료 (추정된)

2028년 5월 31일

연구 등록 날짜

최초 제출

2025년 4월 9일

QC 기준을 충족하는 최초 제출

2025년 4월 23일

처음 게시됨 (실제)

2025년 4월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다